

Rajेशha Rupaimoole

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4691655/publications.pdf>

Version: 2024-02-01

62
papers

9,567
citations

70961

41
h-index

114278

63
g-index

63
all docs

63
docs citations

63
times ranked

19124
citing authors

#	ARTICLE	IF	CITATIONS
1	A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. <i>IScience</i> , 2020, 23, 100878.	1.9	13
2	Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. <i>EBioMedicine</i> , 2019, 43, 127-137.	2.7	48
3	PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 162-172.	1.9	23
4	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018, 78, 3233-3242.	0.4	69
5	Personalized RNA Medicine for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1734-1747.	3.2	67
6	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018, 9, 2923.	5.8	151
7	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. <i>Oncotarget</i> , 2018, 9, 25115-25126.	0.8	24
8	MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 203-222.	21.5	3,558
9	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	3.2	122
10	Role of Platelet-Derived Tgf β 1 in the Progression of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5611-5621.	3.2	51
11	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	9
12	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	5.8	169
13	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. <i>Cell Reports</i> , 2017, 21, 2785-2795.	2.9	32
14	A role for miR-34 in colon cancer stem cell homeostasis. <i>Stem Cell Investigation</i> , 2016, 3, 42-42.	1.3	9
15	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 159-172.	3.6	115
16	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1344-1352.	1.9	41
17	Developing hyperpolarized silicon particles for <i>in vivo</i> MRI targeting of ovarian cancer. <i>Journal of Medical Imaging</i> , 2016, 3, 036001.	0.8	24
18	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	5.8	100

#	ARTICLE	IF	CITATIONS
19	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. <i>Oncogene</i> , 2016, 35, 691-701.	2.6	40
20	Role of Increased n-acetylaspartate Levels in Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv426.	3.0	51
21	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. <i>Cancer Discovery</i> , 2016, 6, 235-246.	7.7	554
22	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. <i>Oncogene</i> , 2016, 35, 4312-4320.	2.6	83
23	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial to Mesenchymal Transition. <i>Journal of Immunology</i> , 2016, 196, 1412-1418.	0.4	66
24	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1713-1724.	3.2	69
25	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. <i>Oncogene</i> , 2016, 35, 2390-2397.	2.6	71
26	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. <i>JCI Insight</i> , 2016, 1, e87754.	2.3	11
27	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	3.9	101
28	Macrophage TGF- β 2 and the Proapoptotic Extracellular Matrix Protein BIGH3 Induce Renal Cell Apoptosis in Prediabetic and Diabetic Conditions. <i>International Journal of Clinical Medicine</i> , 2016, 07, 496-510.	0.1	8
29	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , 2015, 1, 15001.	1.4	3
30	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	102
31	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015, 13, 2395-2402.	2.9	105
32	The ZNF304-integrin axis protects against anoikis in cancer. <i>Nature Communications</i> , 2015, 6, 7351.	5.8	48
33	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. <i>Clinical Cancer Research</i> , 2015, 21, 3286-3297.	3.2	37
34	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1466-1475.	1.9	20
35	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015, 28, 610-622.	7.7	94
36	miR-506 inhibits multiple targets in the epithelial to mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. <i>Journal of Pathology</i> , 2015, 235, 25-36.	2.1	94

#	ARTICLE	IF	CITATIONS
37	Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5331-5336.	3.3	79
38	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. <i>Molecular Systems Biology</i> , 2014, 10, 728.	3.2	255
39	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. <i>Cancer Cell</i> , 2014, 26, 863-879.	7.7	46
40	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3280-3288.	3.2	80
41	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1061-1067.	1.5	34
42	Cross-talk between EphA2 and BRAF/CRaf Is a Key Determinant of Response to Dasatinib. <i>Clinical Cancer Research</i> , 2014, 20, 1846-1855.	3.2	25
43	Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1750-1757.	1.9	31
44	Notch3 Pathway Alterations in Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3282-3293.	0.4	59
45	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014, 5, 5202.	5.8	151
46	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. <i>Nature Communications</i> , 2014, 5, 5203.	5.8	195
47	2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014, 5, 3459.	5.8	103
48	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2876-2885.	1.9	77
49	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	7.7	252
50	Autocrine Effects of Tumor-Derived Complement. <i>Cell Reports</i> , 2014, 6, 1085-1095.	2.9	164
51	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. <i>Cell Reports</i> , 2014, 7, 488-500.	2.9	43
52	Role of Focal Adhesion Kinase in Regulating YAP-Mediated Paclitaxel Resistance in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1485-1495.	3.0	151
53	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013, 4, 2427.	5.8	363
54	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. <i>Cancer Cell</i> , 2013, 23, 186-199.	7.7	340

#	ARTICLE	IF	CITATIONS
55	Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma. <i>Neoplasia</i> , 2013, 15, 502-IN15.	2.3	66
56	A new method for stranded whole transcriptome RNA-seq. <i>Methods</i> , 2013, 63, 126-134.	1.9	59
57	ATP11B mediates platinum resistance in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2119-2130.	3.9	56
58	Complement Component 3 (C3) Is Transcriptionally Regulated By TWIST1. <i>Blood</i> , 2013, 122, 1046-1046.	0.6	1
59	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	13.9	651
60	MicroRNA therapeutics: principles, expectations, and challenges. <i>Chinese Journal of Cancer</i> , 2011, 30, 368-370.	4.9	82
61	MicroRNA therapeutics: principles, expectations, and challenges. <i>Chinese Journal of Cancer</i> , 2011, 30, 368-370.	4.9	1
62	C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells. <i>Matrix Biology</i> , 2009, 28, 347-353.	1.5	19